Bolt Biotherapeutics, Inc.
BOLT
$4.54
-$0.10-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 90.10% | 41.49% | -76.83% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 90.10% | 41.49% | -76.83% | -100.00% |
| Cost of Revenue | -57.45% | -52.59% | -51.42% | -40.87% | -28.18% |
| Gross Profit | 78.77% | 65.47% | 59.78% | 22.41% | 17.64% |
| SG&A Expenses | -21.03% | -12.16% | -27.86% | -34.47% | -28.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.27% | -43.86% | -45.76% | -40.37% | -28.30% |
| Operating Income | 64.23% | 53.15% | 51.61% | 29.12% | 20.73% |
| Income Before Tax | 58.39% | 52.93% | 59.61% | -2.12% | 10.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.39% | 52.93% | 59.61% | -2.12% | 10.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.39% | 52.93% | 59.61% | -2.12% | 10.99% |
| EBIT | 64.23% | 53.15% | 51.61% | 29.12% | 20.73% |
| EBITDA | 64.90% | 53.68% | 52.29% | 29.57% | 21.02% |
| EPS Basic | 53.88% | 53.09% | 59.84% | -1.39% | 11.79% |
| Normalized Basic EPS | 61.14% | 53.09% | 51.72% | 29.21% | 18.69% |
| EPS Diluted | 53.88% | 53.09% | 59.84% | -1.39% | 11.79% |
| Normalized Diluted EPS | 61.14% | 53.09% | 51.72% | 29.21% | 18.69% |
| Average Basic Shares Outstanding | -9.77% | 0.36% | 0.58% | 0.71% | 0.91% |
| Average Diluted Shares Outstanding | -9.77% | 0.36% | 0.58% | 0.71% | 0.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |